Breast Cancer – Expert Insights from Aditya Bardia
Dr Bardia tells us about his early and metastatic breast cancer highlights from ASCO21, including the OlympiA (LBA1), ECOG-ACRIN EA1131 (abstract 605), GeparNUEVO (abstract 506), and VERONICA (abstract 1004) trials, as well as a patient advocate-led survey seeking to understand the views of metastatic breast cancer patients on drug dosing (abstract 1005).
Interviewee: Aditya Bardia
Affiliation(s): Attending Physician, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Disclaimer: Springer Healthcare selected the experts for interview. The expert interviews appearing herein were not prepared or reviewed by ASCO and have not been subject to a peer review process. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. Read full disclaimer here.
Expert insights into key ASCO21 data that will impact clinical practice and patient
care plus complimentary access to 50 official ASCO video presentations and
downloadable slides, picked by our Experts.
ASCO Direct is an officially licensed program of the American Society of Clinical Oncology® (ASCO®)
This program is supported by Bristol Myers Squibb and brought to you by Springer Healthcare